Biology of Blood and Marrow Transplantation
Volume 18, Issue 2 , Pages 162-171, February 2012

NCI, NHLBI/PBMTC First International Conference on Late Effects after Pediatric Hematopoietic Cell Transplantation: Health-Related Quality of Life, Functional, and Neurocognitive Outcomes

  • Susan K. Parsons

      Affiliations

    • Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, Massachusetts
  • ,
  • Sean Phipps

      Affiliations

    • Department of Psychology, St. Jude Children’s Research Hospital, Memphis, Tennessee
  • ,
  • Lillian Sung

      Affiliations

    • Division of Haematology/Oncology and Program in Child Health Evaluative Sciences, The Hospital for Sick Children, Toronto, Ontario, Canada
  • ,
  • K. Scott Baker

      Affiliations

    • Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington
  • ,
  • Michael A. Pulsipher

      Affiliations

    • Division of Hematology/BMT, University of Utah School of Medicine/Primary Children’s Medical Center, Salt Lake City, Utah
    • Corresponding Author InformationCorrespondence and reprint requests: Michael A. Pulsipher, MD, Division of Hematology/BMT, Primary Children’s Medical Center, University of Utah School of Medicine/Huntsman Cancer Institute, 50 North Medical Drive, Salt Lake City, UT.
  • ,
  • Kirsten K. Ness

      Affiliations

    • Epidemiology and Cancer Control, St. Jude Children’s Research Hospital, Memphis, Tennessee

Received 5 December 2011; accepted 5 December 2011. published online 12 December 2011.

The purpose of this manuscript is to summarize issues relevant to health-related quality of life (HRQL), physical function, and neurocognitive function for survivors of pediatric hematopoietic stem cell transplantation (HCT). The physiologic and psychological demands of HCT and its sequelae have the potential to substantially alter HRQL. When compared with research on adult HCT recipients, research in pediatric HRQL following HCT has lagged considerably. Initially, this lag was because of limited validated questionnaires, small numbers of affected patients, and a general lack of salience for the topic relative to traditional endpoints, such as transplant-related toxicity and potential mortality. The percentage of childhood HCT survivors with physical disability ranges from 7% to 17% in studies where the outcome was based on clinician or self-report measures, to over 40% in studies where the outcome was based on a directly measured physical performance task. Direct and comprehensive measures of physical performance may help further clarify the proportion of individuals who have subclinical problems amenable to intervention before apparent functional loss becomes a problem. There is a need to include longer term survivors in such an assessment. In terms of neurocognitive function, the majority of reports demonstrate relatively good function in survivors. However, it is clear that little or no data on outcomes beyond 5 years posttransplant have been obtained, and clinicians working with this population remain concerned regarding the cognitive functions of these survivors. Research focused on these domains should attempt to better understand the prevalence of the problem using child self-report and direct measurements of function, standardize measurement methods, and tools across trials, obtain longer term evaluations and begin to consider interventional trials.

Key Words: Late effects, Pediatric allogeneic transplantation, Pediatric autologous transplantation, Health-related quality of life, Functional outcomes, Neurocognitive outcomes

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Financial disclosure: See Acknowledgments on page 169.

PII: S1083-8791(11)01063-9

doi:10.1016/j.bbmt.2011.12.501

Biology of Blood and Marrow Transplantation
Volume 18, Issue 2 , Pages 162-171, February 2012